ASCO ‘13 – Promise of Novel Targets/Technologies to Unfold At ASCO 2013

Date: 2015-07

New cancer therapies are being developed through targeted approaches that can accelerate development of more efficacious, personalized treatments. Data from such novel targets or technologies (BTK/ PI3K/ PD-1/ next-generation mAbs or ENHANZE tech/ SMDCs / Oncolytic virus / BiTE) for Hematological Malignancies and Solid tumors will be highlighted at ASCO. These include Amgen’s T-VEC (PhIII), Blinatumomab (PhII/III); Gilead’s Idelalisib (PhIII); Regeneron’s REGN910 (SAR307746, PhI), REGN421 (SAR153192, PhI); Endocyte’s Vintafolide (SMDCs, PhII); Halozyme’s PEGPH20 (PhI); Infinity pharma’s IPI-145 (PhI/II); Pharmacyclics’ Ibrutinib (PhIII). This report summarizes application, competitive landscape, commercial potential of novel targets and technologies. For more detail, please read our report released on May 29, 2013, titled, “ASCO ‘13 – Promise of Novel Targets/Technologies to Unfold At ASCO 2013”.

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample